BOLD Stock Summary and Trading Ideas (Boundless Bio | NASDAQ:BOLD)

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Boundless Bio trades on the NASDAQ stock market under the symbol BOLD.

As of November 2, 2026, BOLD stock price declined to $2.44 with 89,682 million shares trading.

BOLD has a beta of 0.47, meaning it tends to be less sensitive to market movements. BOLD has a correlation of 0.01 to the broad based SPY ETF.

BOLD has a market cap of $56.39 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that BOLD belongs to (by Net Assets): VTI, VXF, IWC.

BOLD has outperformed the market in the last year with a price return of +74.3% while the SPY ETF gained +11.4%. However, in the short term, BOLD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.4% vs +0.9% return in SPY. But in the last 2 weeks, BOLD shares have fared better than the market returning +5.6% compared to SPY -1.9%.

BOLD support price is $2.35 and resistance is $2.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BOLD shares will trade within this expected range on the day.